- Home
- EICB vs TNGX Comparison
EICB vs TNGX Comparison
Compare EICB & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EICB
- TNGX
- Stock Information
- Founded
- EICB N/A
- TNGX 2014
- Country
- EICB
- TNGX United States
- Employees
- EICB N/A
- TNGX N/A
- Industry
- EICB
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- EICB
- TNGX Health Care
- Exchange
- EICB Nasdaq
- TNGX Nasdaq
- Market Cap
- EICB N/A
- TNGX 735.0M
- IPO Year
- EICB N/A
- TNGX N/A
- Fundamental
- Price
- EICB $24.94
- TNGX $7.15
- Analyst Decision
- EICB
- TNGX Strong Buy
- Analyst Count
- EICB 0
- TNGX 8
- Target Price
- EICB N/A
- TNGX $15.14
- AVG Volume (30 Days)
- EICB N/A
- TNGX 902.1K
- Earning Date
- EICB N/A
- TNGX 11-06-2024
- Dividend Yield
- EICB N/A
- TNGX N/A
- EPS Growth
- EICB N/A
- TNGX N/A
- EPS
- EICB N/A
- TNGX N/A
- Revenue
- EICB N/A
- TNGX $42,509,000.00
- Revenue This Year
- EICB N/A
- TNGX $18.15
- Revenue Next Year
- EICB N/A
- TNGX N/A
- P/E Ratio
- EICB N/A
- TNGX N/A
- Revenue Growth
- EICB N/A
- TNGX 26.16
- 52 Week Low
- EICB N/A
- TNGX $6.33
- 52 Week High
- EICB N/A
- TNGX $13.01
- Technical
- Relative Strength Index (RSI)
- EICB 48.94
- TNGX 42.73
- Support Level
- EICB $24.85
- TNGX $6.83
- Resistance Level
- EICB $24.99
- TNGX $7.47
- Average True Range (ATR)
- EICB 0.10
- TNGX 0.35
- MACD
- EICB -0.01
- TNGX 0.14
- Stochastic Oscillator
- EICB 21.79
- TNGX 72.25
About EICB Eagle Point Income Company Inc. 7.75% Series B Term Preferred Stock Due 2028
Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.